Nirali N. Shah
National Institutes of Health
231 Papers
312 Citations
Nirali N. Shah is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 156 publications. Previous affiliations of Nirali N. Shah include University of Tennessee Health Science Center & Johns Hopkins University.
Chat about Author
Papers
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
2.8K
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah,Terry J. Fry +1 more
TL;DR: The authors outline the key limitations of CAR T cell therapy, with a focus on mechanisms of resistance, and discuss strategies to improve the efficacy and broaden the applicability of this promising therapeutic approach.
849
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso,Daniel W. Lee,Nirali N. Shah,Maryalice Stetler-Stevenson,Constance M. Yuan,Ira Pastan,Dimiter S. Dimitrov,Richard A. Morgan,David J. FitzGerald,David M. Barrett,Alan S. Wayne,Alan S. Wayne,Crystal L. Mackall,Rimas J. Orentas +13 more
TL;DR: It is concluded that second-generation m971 mAb-derived anti-CD22 CARs are promising novel therapeutics that should be tested in BCP-ALL.
618
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel,Shabnum Patel,Lori Muffly,Nasheed Hossain,Jean Oak,John H. Baird,Matthew J. Frank,Parveen Shiraz,Bita Sahaf,Juliana Craig,Maria Iglesias,Sheren F. Younes,Yasodha Natkunam,Michael G. Ozawa,Eric J Yang,John S. Tamaresis,Harshini Chinnasamy,Zach Ehlinger,Warren D. Reynolds,Rachel C. Lynn,Maria Caterina Rotiroti,Nikolaos Gkitsas,Sally Arai,Laura Johnston,Robert Lowsky,Robbie G. Majzner,Everett Meyer,Robert S. Negrin,Andrew R. Rezvani,Surbhi Sidana,Judith A. Shizuru,Wen-Kai Weng,Chelsea D. Mullins,Allison P. Jacob,Ilan R. Kirsch,Magali Bazzano,Jing Zhou,Sean Mackay,Scott J. Bornheimer,Liora M. Schultz,Liora M. Schultz,Sneha Ramakrishna,Kara L. Davis,Katherine A. Kong,Nirali N. Shah,Haiying Qin,Terry J. Fry,Terry J. Fry,Steven A. Feldman,Crystal L. Mackall,David B. Miklos +50 more
TL;DR: In this article, a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) was tested in a phase I clinical trial of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL.